Health
STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study
TL;DR
- Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.
Short summary
Our full write-up is on its way. For the complete story, read the original report:
Oct 28, 2026 · Updated 10/28/2026, 7:48:06 PM · Reported with: STAT
Sources (2)
NRI Bytes writes its own articles from the reporting below.
STAT — STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head studySTAT — STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes studyUp next · Health
Taylor Swift and Travis Kelce donate $1 million to feed 2.4 million New Yorkers
Read next →
More stories
Health
Over 42,000 candidates to take FMGE on Saturday; NBEMS deploys 4,500-plus personnel, live CCTV surveillance
1h ago
Health
Nearly 1 in 4 cancer drug prices unchanged: Data
1h ago
Health
Doctor explains reasons for respiratory symptoms worsening at night, shares steps to reduce risk
2h ago
Health
4 killed, 2 injured in fire at Delhi shoe factory; owner summoned
1h ago·2 sources
